Speciality Medicines IPO opens: Issue booked 15% so far; check GMP, price band and other key details about SME IPO

-6

Market Impact Score

-100 Bearish+100 Bullish

AI Analysis

The broader pharmaceutical and healthcare sector in India continues to see new listings, particularly in the SME segment. Investor interest in these smaller IPOs often hinges on strong subscription numbers and positive GMP.

Trading Insight

Given the 'nil' GMP, a cautious approach is warranted for this specific SME IPO; focus on fundamental analysis rather than speculative listing gains.

Quick check: TATASTEEL bearish bias (-2.0% 1d), HINDALCO bearish bias (-3.4% 1d).

Key Evidence

•Speciality Medicines IPO opened for bidding today, March 20, 2026.
•The IPO is worth ₹29 crore and is entirely a fresh share sale.
•The issue has been booked 15% so far on Day 1.
•Speciality Medicines IPO GMP (Grey Market Premium) remains nil.
•Risk flag: Low subscription rates could indicate weak investor demand.

Sectors:Pharmaceuticals Healthcare

AI-powered analysis by

Anadi Algo News